What did @dr.jasonpencek actually say?
The creator laid out a three-part "performance stack": get testosterone replacement if you're low, add a growth hormone peptide (his pick is tesamorelin over MK-677, especially for women), and throw in BPC-157 to manage workout-related injuries. He was direct that none of this works without diet, nutrition, and exercise doing the heavy lifting first.
He also made a specific claim about MK-677 increasing appetite, steered women away from it for that reason, and positioned tesamorelin as the fat-loss-forward option. He closed by mentioning he personally takes the stack, works out two to three times a day, and eats one gram of protein per pound of bodyweight. That personal disclosure matters, because it frames this as lived experience rather than a clinical recommendation.
Does the science back this up?
On testosterone replacement for men with documented low levels, yes, the evidence is solid. On tesamorelin for fat loss, there's legitimate clinical data. On MK-677 and appetite, he's right. On BPC-157 in humans, the evidence is thin.
Testosterone replacement therapy in hypogonadal men consistently improves lean mass and reduces fat mass. Bhasin et al. (2001, New England Journal of Medicine) remains a landmark here. But the creator's framing, "get on some testosterone" without stressing the need for confirmed low levels first, glosses over the real risks of using testosterone when levels are normal.
Tesamorelin has FDA approval for HIV-associated lipodystrophy, and studies like Falutz et al. (2010, Journal of Clinical Endocrinology and Metabolism) show meaningful visceral fat reduction. Its use in healthy adults without lipodystrophy is off-label, and the fat-loss effects in that population are less established.
MK-677 does raise IGF-1 and does increase appetite. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed both. His gender-based rationale for avoiding it in women is practical, not clinical science, but it's not wrong either.
BPC-157 human data is essentially nonexistent. Animal studies are promising (Sikiric et al., 2018, Current Pharmaceutical Design), but calling it an injury-reduction tool for humans is getting ahead of the evidence by a significant margin.
What did they get wrong (or right)?
He got the testosterone framing mostly right by anchoring it to low levels, but the casual delivery of "get on some testosterone" could lead viewers to self-diagnose deficiency without bloodwork. That's a real problem.
The tesamorelin positioning is reasonable, though presenting it as a general performance peptide sidesteps its actual regulatory status. It is not approved for body composition optimization in otherwise healthy people, and compounded versions are not equivalent to the FDA-approved formulation Egrifta. That distinction matters legally and clinically.
The BPC-157 claim is the weakest point in the video. Saying it helps "reduce injuries that you see from actually working out too much" implies a clinical effect in humans that has not been demonstrated in peer-reviewed human trials. Rodent data showing tendon and gut healing is not a prescription for gym recovery.
What he genuinely got right: the insistence that the stack does nothing without training and nutrition is both accurate and responsible. That disclaimer is more honest than most performance-stack content on this platform.
What should you actually know?
If you're considering any of these compounds, there are things this video does not tell you that you need to hear.
- Testosterone replacement is appropriate for confirmed hypogonadism, not for optimizing performance in people with normal levels. Unsupervised use carries risks including erythrocytosis, cardiovascular strain, and suppression of natural production.
- Tesamorelin is an FDA-approved drug for a specific condition. Off-label use for fat loss in healthy adults is legal for physicians to prescribe, but the evidence base is narrower than the video implies.
- MK-677 is not FDA-approved for any indication. It is a research compound. Long-term safety data in humans is limited, and increased appetite combined with elevated IGF-1 has implications for insulin resistance that the creator did not mention.
- BPC-157 has no completed human clinical trials for musculoskeletal injury. Using it for gym recovery is based on extrapolation from animal research. That does not mean it is dangerous, but it means the confidence level the creator projects is not supported by evidence.
- A stack this complex requires monitoring. Blood panels, not a single hormone check, are the minimum baseline before starting any of these compounds.